Sensipar Approval History
- FDA approved: Yes (First approved March 8th, 2004)
- Brand name: Sensipar
- Generic name: cinacalcet
- Company: Amgen Inc.
- Treatment for: Secondary Hyperparathyroidism, Hypercalcemia of Malignancy
Sensipar (cinacalcet) is a calcimimetic agent indicated for the treatment of secondary hyperparathyroidism in dialysis patients and for the treatment of hypercalcemia in patients with parathyroid carcinoma.
Development History and FDA Approval Process for Sensipar
|Mar 8, 2004||Sensipar Amgen Inc. - Treatment for Secondary Hyperparathyroidism in dialysis patients|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.